

Publications for Nick Pavlakis

2019

Sabari, J., Offin, M., Stephens, D., Ni, A., Lee, A., Pavlakis, N., Clarke, S., Diakos, C., Datta, S., Tandon, N., et al (2019). A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. *Journal of the National Cancer Institute*, 111(6), 1-9. [More Information]

2018

Chan, J., Diakos, C., Chan, D., Engel, A., Pavlakis, N., Gill, A., Clarke, S. (2018). A Longitudinal Investigation of Inflammatory Markers in Colorectal Cancer Patients Perioperatively Demonstrates Benefit in Serial Remeasurement. *Annals of Surgery*, 267(6), 1119-1125. [More Information]

Oh, B., Yeung, A., Klein, P., Larkey, L., Ee, C., Zaslowski, C., Knobf, M., Payne, P., Stener-Victorin, E., Lee, R., Pavlakis, N., Boyle, F., Clarke, S., Back, M., et al (2018). Accreditation Standard Guideline Initiative for Tai Chi and Qigong Instructors and Training Institutions. *Medicines*, 5(2), 51. [More Information]

Oh, B., Eade, T., Kneebone, A., Hruby, G., Lamoury, G., Pavlakis, N., Clarke, S., Zaslowski, C., Marr, I., Costa, D., Back, M. (2018). Acupuncture in Oncology: The Effectiveness of Acupuncture May Not Depend on Needle Retention Duration. *Integrative Cancer Therapies*, 17(2), 458-466. [More Information]

Tang, M., Price, T., Shapiro, J., Gibbs, P., Haller, D., Arnold, D., Peeters, M., Segelov, E., Roy, A., Tebbutt, N., Pavlakis, N., et al (2018). Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. *Expert Review of Anticancer Therapy*, 18(4), 339-349. [More Information]

Li, B., Shen, R., Buonocore, D., Olah, Z., Ni, A., Ginsberg, M., Ulaner, G., Offin, M., Feldman, D., Hembrough, T., Pavlakis, N., Clarke, S., et al (2018). Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. *Journal of Clinical Oncology*, 36(24), 2532-2537. [More Information]

Ameratunga, M., Pavlakis, N., Wheeler, H., Grant, R., Simes, R., Khasraw, M. (2018). Anti-angiogenic therapy for high-grade glioma. *Cochrane Database of Systematic Reviews*, 2018(11), 1-52. [More Information]

Metaxas, Y., Rivalland, G., Mauti, L., Klingbiel, D., Kao, S., Schmid, S., Nowak, A., Gautschi, O., Bartnick, T., Pavlakis, N., et al (2018). Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. *Journal of Thoracic Oncology*, 13(11), 1784-1791. [More Information]

Shapiro, J., Thavaneswaran, S., Underhill, C., Robledo, K., Karapetis, C., Day, F., Nott, L., Jefford, M., Chantrill, L., Pavlakis, N., Khasraw, M., Simes, R., GebSKI, V., et al (2018). Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. *Clinical Colorectal Cancer*, 17(4), 313-319. [More Information]

Lane, R., Khin, N., Pavlakis, N., Hugh, T., Clarke, S., Magnussen, J., Rogan, C., Flekser, R. (2018). Challenges in chemotherapy delivery: comparison of standard chemotherapy delivery to locoregional vascular mass fluid transfer. *Future Oncology*, 14(7), 647-663. [More Information]

River, J., McKenzie, H., Levy, D., Pavlakis, N., Back, M., Oh, B. (2018). Convergent priorities and tensions: a qualitative study of the integration of complementary and alternative therapies with conventional cancer treatment. *Supportive Care in Cancer*, 26(6), 1791-1797. [More Information]

Itchins, M., Clarke, S., Pavlakis, N. (2018). Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?-the shifting paradigm of therapeutics. *Translational Lung Cancer Research*, 7(Suppl 1), S39-S45. [More Information]

Chan, D., Thompson, R., Lam, M., Pavlakis, N., Hallet, J., Law, C., Singh, S., Myrehaug, S. (2018). External Beam Radiotherapy in the Treatment of Gastroenteropancreatic Neuroendocrine Tumours: A Systematic Review. *Clinical Oncology*, 30(7), 400-408. [More Information]

Chan, D., Moody, L., Segelov, E., Metz, D., Strosberg, J., Pavlakis, N., Singh, S. (2018). Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS). *Neuroendocrinology*, 107(1), 32-41. [More Information]

Singh, S., Moody, L., Chan, D., Metz, D., Strosberg, J., Asmis, T., Bailey, D., Bergsland, E., Pavlakis, N., Segelov, E., et al (2018). Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. *JAMA Oncology*, 4(11), 1597-1604. [More Information]

Martin, A., Gibbs, E., Sjoquist, K., Pavlakis, N., Simes, R., Price, T., Shannon, J., Gill, S., Jain, V., Liu, G., et al (2018). Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. *Gastric Cancer*, 21(3), 473-480. [More Information]

- Townend, P., de Reuver, P., Chua, T., Mittal, A., Clark, S., Pavlakis, N., Gill, A., Samra, J. (2018). Histopathological tumour viability after neoadjuvant chemotherapy influences survival in resected pancreatic cancer: analysis of early outcome data. *ANZ Journal of Surgery*, 88(3), E167-E172. [More Information]
- Sud, S., O'Callaghan, C., Jonker, C., Karapetis, C., Price, T., Tebbutt, N., Shapiro, J., Hazel, G., Pavlakis, N., Gibbs, P., et al (2018). Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response. *Current Oncology*, 25(6), e516-e526. [More Information]
- Pavlakis, N., Tan, A., Chan, D., Faisal, W. (2018). New drug developments in metastatic gastric cancer. *Therapeutic Advances in Gastroenterology*, 11, 1-13. [More Information]
- Hayes, A., Brungs, D., Pavlakis, N. (2018). Osteoclast inhibitors to prevent bone metastases in men with high-risk, nonmetastatic prostate cancer: A systematic review and meta-Analysis. *PloS One*, 13(1), 1-14. [More Information]
- Itchins, M., Hayes, S., Gill, A., Cooper, W., O'Connell, R., Howell, V., Clarke, S., Pavlakis, N. (2018). Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis. *Asia-Pacific Journal of Clinical Oncology*, 14(5), e275-e282. [More Information]
- Itchins, M., Arena, J., Pavlakis, N., Nahm, C., Gibbs, E., Mohamudally, A., Maher, R., Bailey, D., Schembri, G., Gill, A., Diakos, C., Khasraw, M., Hrubby, G., Kneebone, A., Mittal, A., Samra, J., Clarke, S., et al (2018). Pattern of care and survival of pancreatic ductal adenocarcinoma in a multi-disciplinary high-volume centre. *Gastroenterology & Hepatology*, 9(5), 185-189. [More Information]
- Tapia Rico, G., Li, M., Pavlakis, N., Cehic, G., Price, T. (2018). Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions. *Cancer Treatment Reviews*, 66, 1-6. [More Information]
- Crumbaker, M., Guminski, A., Gurney, H., Sabanathan, D., Wong, S., Pavlakis, N. (2018). Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia. *Asia-Pacific Journal of Clinical Oncology*, 14(2), e45-e49. [More Information]
- Lee, A., Howell, V., Itchins, M., Wheeler, H., Pavlakis, N. (2018). ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses. *Clinical Lung Cancer*, 19(5), 457-459. [More Information]
- Price, T., Tang, M., Gibbs, P., Haller, D., Peeters, M., Arnold, D., Segelov, E., Roy, A., Tebbutt, N., Pavlakis, N., et al (2018). Targeted therapy for metastatic colorectal cancer. *Expert Review of Anticancer Therapy*, 18(10), 991-1006. [More Information]
- Lane, R., Khin, N., Rogan, C., Magnussen, J., Ho-Shon, K., Pavlakis, N., Clarke, S., Hugh, T. (2018). The integration of pharmacology and pathophysiology into locoregional chemotherapy delivery via mass fluid transfer. *Journal of Controlled Release*, 292, 18-28. [More Information]
- Hayes, S., Clarke, S., Pavlakis, N., Howell, V. (2018). The role of proteomics in the age of immunotherapies. *Mammalian Genome*, 29, 757-769. [More Information]
- Brown, K., Xue, A., Julovi, S., Gill, A., Pavlakis, N., Samra, J., Smith, R., Hugh, T. (2018). Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity. *Journal of Surgical Research*, 227, 158-167. [More Information]

2017

- O'Carrigan, B., Wong, M., Willson, M., Stockler, M., Pavlakis, N., Goodwin, A. (2017). Bisphosphonates and other bone agents for breast cancer. *Cochrane Database of Systematic Reviews*, 2017 (10), 1-210. [More Information]
- Willowson, K., Hayes, A., Chan, D., Tapner, M., Bernard, E., Maher, R., Pavlakis, N., Clarke, S., Bailey, D. (2017). Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis. *EJNMMI Research*, 7(1), 1-13. [More Information]
- Chan, D., Pavlakis, N., Schembri, G., Bernard, E., Hsiao, E., Hayes, A., Barnes, T., Diakos, C., Khasraw, M., Samra, J., Eslick, E., Roach, P., Engel, A., Clarke, S., Bailey, D. (2017). Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: proposal for a Novel Grading Scheme with Prognostic Significance. *Theranostics*, 7(5), 1149-1158. [More Information]
- Chan, D., Segelov, E., Wong, R., Smith, A., Herbertson, R., Li, B., Tebbutt, N., Price, T., Pavlakis, N. (2017). Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. *Cochrane Database of Systematic Reviews*, 2017 (6), 1-175. [More Information]
- Chan, D., Ferone, D., Albertelli, M., Pavlakis, N., Segelov, E., Singh, S. (2017). Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. *Endocrine*, 57(3), 366-375. [More Information]
- Oh, B., Eade, T., Kneebone, A., Pavlakis, N., Clarke, S., Eslick, G., River, J., Back, M. (2017). Factors affecting whether or not cancer patients consider using acupuncture. *Acupuncture in Medicine*, 35(2), 107-113. [More Information]

Segelov, E., Chan, D., Lawrence, B., Pavlakis, N., Kennecke, H., Jackson, C., Law, C., Singh, S. (2017). Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration. *Journal of Global Oncology*, 3(4), 380-388. [More Information]

Tan, A., Heimberger, A., Menzies, A., Pavlakis, N., Khasraw, M. (2017). Immune Checkpoint Inhibitors for Brain Metastases. *Current Oncology Reports*, 19(6), 1-12. [More Information]

Johns, A., McKay, S., Humphris, J., Pinese, M., Chantrell, L., Mead, S., Tucker, K., Andrews, L., Goodwin, A., Leonard, C., Pavlakis, N., Gill, A., et al (2017). Lost in translation: Returning germline genetic results in genome-scale cancer research. *Genome Medicine*, 9(1), 1-9. [More Information]

Chan, D., Clarke, S., Diakos, C., Roach, P., Bailey, D., Singh, S., Pavlakis, N. (2017). Prognostic and predictive biomarkers in neuroendocrine tumours. *Critical Reviews in Oncology/Hematology*, 113, 268-282. [More Information]

Itchins, M., Arena, J., Nahm, C., Rabindran, J., Kim, S., Gibbs, E., Bergamin, S., Chua, T., Gill, A., Maher, R., Diakos, C., Mittal, A., Hruby, G., Kneebone, A., Pavlakis, N., Samra, J., Clarke, S., et al (2017). Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre. *European Journal of Surgical Oncology*, 43(9), 1711-1717. [More Information]

van Zandwijk, N., Pavlakis, N., Kao, S., Linton, A., Boyer, M., Clarke, S., Huynh, Y., Chrzanoska, A., Fulham, M., Bailey, D., Cooper, W., Kritharides, L., Reid, G., et al (2017). Safety and activity of microRNA-loaded micelles in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. *The Lancet Oncology*, 18(10), 1386-1396. [More Information]

Selinger, C., Li, B., Pavlakis, N., Links, M., Gill, A., Lee, A., Clarke, S., Tran, T., Lum, T., Yip, P., Horvath, L., Yu, B., O'Toole, S., Cooper, W., et al (2017). Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. *Histopathology*, 70(3), 402-411. [More Information]

Lee, A., Chan, D., Wong, M., Li, B., Lumba, S., Clarke, S., Samra, J., Pavlakis, N. (2017). Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors. *Neuroendocrinology*, 104(3), 209-222. [More Information]

Chan, D., Sjoquist, K., Goldstein, D., Price, T., Martin, A., Bang, Y., Kang, Y., Pavlakis, N. (2017). The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. *PloS One*, 12(2), 1-16. [More Information]

Information]

Itchins, M., Pavlakis, N. (2017). The evolving landscape of treatment for advanced gastric cancer and the role of anti-angiogenic therapy: Implications from results of the INTEGRATE study. *Translational Gastroenterology and Hepatology*, 2017 (APR), 1-4. [More Information]

Chan, J., Chan, D., Diakos, C., Engel, A., Pavlakis, N., Gill, A., Clarke, S. (2017). The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer. *Annals of Surgery*, 265(3), 539-546. [More Information]

Itchins, M., Chia, P., Hayes, S., Howell, V., Gill, A., Cooper, W., John, T., Mitchell, P., Millward, M., Clarke, S., Pavlakis, N., et al (2017). Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context. *Asia-Pacific Journal of Clinical Oncology*, 13, 3-13. [More Information]

Anthony, L., Ervine, C., Lapuerta, P., Kulke, M., Kunz, P., Bergsland, E., Horsch, D., Metz, D., Pasiaka, J., Pavlakis, N., et al (2017). Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-Controlled Study of Telotristat Ethyl. *Clinical Therapeutics*, 39(11), 2158-2168. [More Information]

2016

Kao, S., Kirschner, M., Cooper, W., Tran, T., Burgers, S., Wright, C., Korse, T., van den Broek, D., Edelman, J., Vallely, M., McCaughan, B., Pavlakis, N., Clarke, S., van Zandwijk, N., Reid, G., et al (2016). A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. *British Journal of Cancer*, 114(5), 524-531. [More Information]

Chan, D., Espinoza, D., Chan, J., Lee, A., Faisal, W., Segelov, E., Pavlakis, N. (2016). Adjuvant anti-VEGF therapy for overall survival and relapse-free survival in patients with resected non-metastatic colorectal cancer (protocol). *Cochrane Database of Systematic Reviews*, 2016 (12), 1-14. [More Information]

Reid, G., Kao, S., Pavlakis, N., Brahmabhatt, H., MacDiarmid, J., Clarke, S., Boyer, M., van Zandwijk, N. (2016). Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. *Epigenomics*, 8(8), 1079-1085. [More Information]

Hayes, S., Haefliger, S., Harris, B., Pavlakis, N., Clarke, S., Molloy, M., Howell, V. (2016). Exhaled breath condensate for lung cancer protein analysis: a review of methods and biomarkers. *Journal of Breath Research*, 10(3), 1-26. [More Information]

Schofield, P., Stockler, M., Zannino, D., Tebbutt, N., Price, T., Simes, R., Wong, N., Pavlakis, N., Ransom, D., Moylan, E., Wilcken, N., et al (2016). Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal

cancer. *Supportive Care in Cancer*, 24(1), 401-408. [More Information]

Segelov, E., Waring, P., Desai, J., Wilson, C., GebSKI, V., Thavaneswaran, S., Elez, E., Underhill, C., Pavlakis, N., Chantrill, L., Khasraw, M., et al (2016). ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. *BMC Cancer*, 16(1), 1-8. [More Information]

Tebbutt, N., Price, T., Ferraro, D., Wong, N., Veillard, A., Hall, M., Sjoquist, K., Pavlakis, N., Strickland, A., Varma, S., GebSKI, V., et al (2016). Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTX3 phase II trial. *British Journal of Cancer*, 114(5), 505-509. [More Information]

Pavlakis, N., Sjoquist, K., Martin, A., Tsobanis, E., Yip, S., Kang, Y., Bang, Y., Alcindor, T., O'Callaghan, C., Burnell, M., Wong, K., Simes, R., et al (2016). Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II Trial. *Journal of Clinical Oncology*, 34(23), 2728-2735. [More Information]

Segelov, E., Thavaneswaran, S., Waring, P., Desai, J., Robledo, K., GebSKI, V., Elez, E., Nott, L., Karapetis, C., Lunke, S., Pavlakis, N., Khasraw, M., Wilson, K., Simes, R., et al (2016). Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. *Journal of Clinical Oncology*, 34(19), 2258-2264. [More Information]

Lane, R., Khin, N., Rogan, C., Magnussen, J., Pavlakis, N., Lane, D., Clarke, S. (2016). Safety and Feasibility of Repeatable Hepatic Vascular Isolation Chemotherapy: A Pilot Study. *Annals of Surgical Oncology*, 23(11), 3699-3708. [More Information]

Wong, M., Chan, D., Lee, A., Li, B., Lumba, S., Clarke, S., Samra, J., Pavlakis, N. (2016). Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). *PloS One*, 11(6), 1-15. [More Information]

Patel, D., Chan, D., Cehic, G., Pavlakis, N., Price, A. (2016). Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors. *Expert Review of Endocrinology & Metabolism*, 11(4), 311-327. [More Information]

Li, B., Barnes, T., Chan, D., Naidoo, J., Lee, A., Khasraw, M., Marx, G., Kris, M., Clarke, S., Drilon, A., Pavlakis, N., et al (2016). The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. *Lung Cancer*, 102, 21-27. [More Information]

Wong, M., Xue, A., Baxter, R., Pavlakis, N., Smith, R. (2016). Upstream and Downstream Co-inhibition of Mitogen-Activated

Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma. *NeoPlasia: an international journal of oncology research*, 18(7), 425-435. [More Information]

2015

Davidson, A., Veillard, A., Tognela, A., Chan, M., Hughes, B., Boyer, M., Briscoe, K., Begbie, S., Abdi, E., Crombie, C., Chinchin, S., Espinoza, D., Coskinas, X., Pavlakis, N., Stockler, M., et al (2015). A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial. *Annals of Oncology*, 26(11), 2280-2286. [More Information]

Kao, S., Fulham, M., Wong, K., Cooper, W., Brahmabhatt, H., MacDiarmid, J., Pattison, S., Sagong, J., Huynh, Y., Leslie, F., Pavlakis, N., Clarke, S., Boyer, M., Reid, G., van Zandwijk, N. (2015). A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. *American Journal of Respiratory and Critical Care Medicine*, 191(12), 1467-1469. [More Information]

Mahon, K., Lin, H., Castillo, L., Lee, B., Lee-Ng, K., Chatfield, M., Chiam, K., Breit, S., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Horvath, L., et al (2015). Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. *British Journal of Cancer*, 112(8), 1340-1348. [More Information]

Chan, D., Pavlakis, N., Shapiro, J., Price, T., Karapetis, C., Tebbutt, N., Segelov, E. (2015). Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature. *PloS One*, 10(8), 1-17. [More Information]

Park, W., Li, B., Maher, R., Samra, J., Clarke, S., Bernard, E., Bailey, D., Pavlakis, N. (2015). Dramatic response to selective internal radiation therapy for unresectable hepatocellular carcinoma. *Oxford Medical Case Reports*, 2015 (2), 194-195. [More Information]

Selinger, C., Cooper, W., Lum, T., McNeil, C., Morey, A., Waring, P., Amanuel, B., Millward, M., Peverall, J., Van Vliet, C., Pavlakis, N., Gill, A., et al (2015). Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing. *Histopathology*, 67(5), 654-663. [More Information]

Davis, I., Long, A., Yip, S., Espinoza, D., Thompson, J., Kichenadasse, G., Harrison, M., Lowenthal, R., Pavlakis, N., Azad, A., Hudson, A., Stockler, M., Martin, A., et al (2015). EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma. *Annals of Oncology*, 26(6), 1118-1123. [More Information]

Li, B., Lee, A., O'Toole, S., Cooper, W., Yu, B., Chaft, J., Arcila, M., Kris, M., Pavlakis, N. (2015). HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. *Lung Cancer*, 90(3), 617-619. [More Information]

Information]

Lee, C., Wu, Y., Ding, P., Lord, S., Inoue, A., Zhou, C., Mitsudomi, T., Rosell, R., Pavlakakis, N., Links, M., GebSKI, V., et al (2015). Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. *Journal of Clinical Oncology*, 33(17), 1958-1965. [More Information]

Zardawi, S., Li, B., Zauderer, M., Wang, J., Atmore, B., Barnes, T., Pavlakakis, N., Mathur, M., Clarke, S. (2015). Localized malignant pleural mesothelioma with renal metastasis. *Oxford Medical Case Reports*, 2015 (1), 170-172. [More Information]

Chan, D., Clarke, S., Gill, A., Chantrill, L., Samra, J., Li, B., Barnes, T., Nahar, K., Pavlakakis, N. (2015). Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report. *Molecular and Clinical Oncology*, 3(4), 817-819. [More Information]

Chantrill, L., Nagrial, A., Watson, C., Johns, A., Martyn-Smith, M., Simpson, S., Mead, S., Jones, M., Samra, J., Gill, A., Chin, V., Sebastian, L., Sjoquist, K., Yip, S., Pavlakakis, N., Grimison, P., Simes, R., et al (2015). Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPACT) Trial. *Clinical Cancer Research*, 21(9), 2029-2037. [More Information]

Hasovits, C., Pavlakakis, N. (2015). Rare molecular subsets among lung tumours - what makes them stand apart from the common? *Cancer Forum*, 39(1), 35-40.

Mehta, S., de Reuver, P., Gill, P., Andrici, J., Dâ€™Urso, L., Mittal, A., Pavlakakis, N., Clarke, S., Samra, J., Gill, A. (2015). Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors. *Medicine*, 94(40), 1-6. [More Information]

2014

Wang, F., Gill, A., Neale, M., Puttaswamy, V., Gananadha, S., Pavlakakis, N., Clarke, S., Hugh, T., Samra, J. (2014). Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma. *Annals of Surgical Oncology*, 21(6), 1937-1947. [More Information]

Khasraw, M., Ameratunga, M., Grant, R., Wheeler, H., Pavlakakis, N. (2014). Antiangiogenic therapy for high-grade glioma. *Cochrane Database of Systematic Reviews*, 2014 (9), 1-42. [More Information]

Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. *British Journal of Cancer*, 110(10), 2462-2471. [More Information]

Wong, M., Xue, A., Julovi, S., Pavlakakis, N., Samra, J., Hugh,

T., Gill, A., Peters, L., Baxter, R., Smith, R. (2014). Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. *Clinical Cancer Research*, 20(10), 4047-4058. [More Information]

Price, T., Segelov, E., Burge, M., Haller, D., Tebbutt, N., Karapetis, C., Punt, C., Pavlakakis, N., Arnold, D., Gibbs, P., et al (2014). Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. *Expert Review of Anticancer Therapy*, 14(12), 1477-1493. [More Information]

Oh, B., Butow, P., Boyle, F., Beale, P., Costa, D., Pavlakakis, N., Bell, D., Davis, E., Choi, S., Lee, M., Clarke, S., et al (2014). Effects of Qigong on Quality of Life, Fatigue, Stress, Neuropathy, and Sexual Function in Women with Metastatic Breast Cancer: A Feasibility Study. *International Journal of Physical Medicine & Rehabilitation*, 2(4), 1-6. [More Information]

Houang, M., Sioson, L., Clarkson, A., Watson, N., Mahtab, F., Toon, C., Raut, A., O'Toole, S., Cooper, W., Pavlakakis, N., Gill, A., et al (2014). EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. *Pathology*, 46(6), 501-508. [More Information]

Li, M., Chan, D., Pavlakakis, N., Kneebone, A., Bailey, D., Clarke, S. (2014). Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction. *Oxford Medical Case Reports*, 2014 (6), 105-106. [More Information]

Ameratunga, M., Pavlakakis, N., GebSKI, V., Broad, A., Khasraw, M. (2014). Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis. *Asia-Pacific Journal of Clinical Oncology*, 10(3), 273-278. [More Information]

Hudson, A., Weir, C., Moon, E., Harvie, R., Klebe, S., Clarke, S., Pavlakakis, N., Howell, V. (2014). Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. *Scientific Reports*, 4, 1-11. [More Information]

Linton, A., Pavlakakis, N., O'Connell, R., Soeberg, M., Kao, S., Clarke, S., Vardy, J., van Zandwijk, N. (2014). Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. *British Journal of Cancer*, 111(9), 1860-1869. [More Information]

Cooper, W., Fox, S., O'Toole, S., Morey, A., Frances, G., Pavlakakis, N., O'Brien, K., Dettrick, A., Leong, T., Rathi, V., et al (2014). National Working Group Meeting on ALK diagnostics in lung cancer. *Asia-Pacific Journal of Clinical Oncology*, 10(S 2), 11-17. [More Information]

Paik, J., Toon, C., Benn, D., High, H., Hasovitz, C., Pavlakakis, N., Clifton-Bligh, R., Gill, A. (2014). Renal Carcinoma

Associated With Succinate Dehydrogenase B Mutation: A New and Unique Subtype of Renal Carcinoma. *Journal of Clinical Oncology*, 32(6), e10-e13. [More Information]

Toon, C., Hasovits, C., Paik, J., Field, M., Chou, A., Hugh, T., Pavlakis, N., Gill, A. (2014). Skin rash, a kidney mass and a family mystery dating back to World War II. *Medical Journal of Australia*, 201(1), 58-60. [More Information]

Weir, C., Hudson, A., Moon, E., Ross, A., Alexander, M., Peters, L., Langova, V., Clarke, S., Pavlakis, N., Davey, R., Howell, V. (2014). Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. *Cancer Immunology Research*, 2(5), 469-479. [More Information]

Govi, S., Christie, D., Mappa, S., Marturano, E., Bruno-Ventre, M., Messina, C., Medina, E., Porter, D., Radford, J., Heo, D., et al (2014). The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study). *Leukemia & Lymphoma*, 55(8), 1796-1799. [More Information]

Segelov, E., Chan, D., Shapiro, J., Price, T., Karapetis, C., Tebbutt, N., Pavlakis, N. (2014). The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. *British Journal of Cancer*, 111(6), 1122-1131. [More Information]

2013

Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Stockler, M., et al (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. *Lung Cancer*, 81(3), 422-427. [More Information]

Vickers, M., Karapetis, C., Tu, D., O'Callaghan, C., Price, T., Tebbutt, N., van Hazel, G., Shapiro, J., Pavlakis, N., Gibbs, P., Simes, R., et al (2013). Association of hypomagnesaemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. *Annals of Oncology*, 24(4), 953-960. [More Information]

Price, T., Segelov, E., Burge, M., Haller, D., Ackland, S., Tebbutt, N., Karapetis, C., Pavlakis, N., Sobrero, A., Cunningham, D., et al (2013). Current opinion on optimal treatment for colorectal cancer. *Expert Review of Anticancer Therapy*, 13(5), 597-611. [More Information]

Tebbutt, N., Parry, M., Zannino, D., Strickland, A., van Hazel, G., Pavlakis, N., Ganju, V., Mellor, D., Dobrovic, A., Gebbski, V. (2013). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTX2 trial. *British Journal of Cancer*, 108(4), 771-774. [More

Information]

Hasovits, C., Pavlakis, N. (2013). EGFR-Targeted therapy and resistance. *Cancer Forum*, 37(2), 166-170.

van Zandwijk, N., Clarke, C., Henderson, D., Musk, A., Fong, K., Nowak, A., Loneragan, R., McCaughan, B., Boyer, M., Feigen, M., et al (2013). Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. *Journal of Thoracic Disease*, 5(6), E254-E307. [More Information]

Kao, S., Vardy, J., Harvie, R., Chatfield, M., van Zandwijk, N., Clarke, S., Pavlakis, N. (2013). Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. *Supportive Care in Cancer*, 21(3), 697-705. [More Information]

Pavlakis, N., Solomon, B. (2013). Lung cancer beyond 2013: Many different diseases. *Cancer Forum*, 37(2), 143-145.

Clarke, S., Karapetis, C., Gibbs, P., Pavlakis, N., Desai, J., Michael, M., Tebbutt, N., Price, T., Taberner, J. (2013). Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors. *Critical Reviews in Oncology / Hematology (online)*, 85(2), 121-135. [More Information]

Hasovits, C., Pavlakis, N., Howell, V., Gill, A., Clarke, S. (2013). Resistance to EGFR targeted antibodies - expansion of clones present from the start of treatment. The more things change, the more they stay the same (Plus ca change, plus ca ne change pas!). *Translational Gastrointestinal Cancer*, 28(1), 44-46. [More Information]

Buikhuisen, W., Burgers, J., Vincent, A., Korse, C., van Klaveren, R., Schramel, F., Pavlakis, N., Nowak, A., Custers, F., Schouwink, J., et al (2013). Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. *The Lancet Oncology*, 14(6), 543-551. [More Information]

Cummins, M., Pavlakis, N. (2013). The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events. *Therapeutic Advances in Medical Oncology*, 5(5), 286-300. [More Information]

Kao, S., Vardy, J., Chatfield, M., Corte, P., Pavlakis, N., Clarke, C., van Zandwijk, N., Clarke, S. (2013). Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data from Patients Seeking Compensation from the New South Wales Dust Diseases Board. *Clinical Lung Cancer*, 14(1), 70-77. [More Information]

2012

Michael, M., Pavlakis, N., Clingan, P., de Boer, R., Johnston, M., Clarke, S. (2012). A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. *Oncology Reports*, 28(3), 763-767. [More

Information]

Wong, M., Stockler, M., Pavlakis, N. (2012). Bisphosphonates and other bone agents for breast cancer (Review). *The Cochrane Library Chichester UK: John Wiley and Sons Ltd*, 2, 1-136. [More Information]

Weickhardt, A., Price, T., Chong, G., GebSKI, V., Pavlakis, N., Johns, T., Azad, A., Skrinos, E., Fluck, K., Dobrovic, A., et al (2012). Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. *Journal of Clinical Oncology*, 30(13), 1505-1512. [More Information]

Oh, B., Butow, P., Mullan, B., Clarke, S., Beale, P., Pavlakis, N., Lee, M., Rosenthal, D., Larkey, L., Vardy, J. (2012). Effect of Medical Qigong on Cognitive function, Quality of Life and a Biomarker of Inflammation in Cancer Patients: A Randomized Controlled Trial. *Supportive Care in Cancer*, 20(6), 1235-1242. [More Information]

Boyer, M., Horwood, K., Pavlakis, N., de Souza, P., Millward, M., Stein, B., Johnston, M., Abell, F., Rischin, D. (2012). Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. *Asia-Pacific Journal of Clinical Oncology*, 8(3), 248-254. [More Information]

Price, T., Shapiro, J., Segelov, E., Karapetis, C., Pavlakis, N., Van Cutsem, E., Shah, M., Kang, Y., Tebbutt, N. (2012). Management of advanced gastric cancer. *Expert Review of Gastroenterology and Hepatology*, 6(2), 199-209. [More Information]

Biankin, A., Waddell, N., Kassahn, K., Gingras, M., Muthuswamy, L., Johns, A., Miller, D., Wilson, P., Patch, A., Wu, J., Gill, A., Kench, J., Pavlakis, N., Lam, V., Richardson, A., Samra, J., et al (2012). Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature*, 491(7424), 399-405. [More Information]

Bester, L., Meteling, B., Pocock, N., Pavlakis, N., Chua, T., Saxena, A., Morris, D. (2012). Radioembolization versus Standard Care of Hepatic Metastases: Comparative Retrospective Cohort Study of Survival Outcomes and Adverse Events in Salvage Patients. *Journal of Vascular and Interventional Radiology*, 23(1), 96-105. [More Information]

Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., Marx, G., Cullen, M., Kerestes, Z., Pavlakis, N. (2012). The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. *Lung Cancer*, 75(2), 248-254. [More Information]

2011

Paech, D., Weston, A., Pavlakis, N., Gill, A., Rajan, N., Barraclough, H., Fitzgerald, B., Van Kooten, M. (2011). A Systematic Review of the Interobserver Variability for

Histology in the Differentiation between Squamous and Nonsquamous Non-small Cell Lung Cancer. *Journal of Thoracic Oncology*, 6(1), 55-63. [More Information]

Asmis, T., Powell, E., Karapetis, C., Jonker, D., Tu, D., Jeffery, M., Pavlakis, N., Gibbs, P., Zhu, L., Dueck, D., et al (2011). Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)-results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. *Annals of Oncology*, 22, 118-126. [More Information]

Standfield, L., Weston, A., Barraclough, H., Van Kooten, M., Pavlakis, N. (2011). Histology as a treatment effect modifier in advanced non-small cell lung cancer: A systematic review of the evidence. *Respirology*, 16(8), 1210-1220. [More Information]

2010

Khasraw, M., Lassman, A., Wheeler, H., Pavlakis, N. (2010). Anti-angiogenic therapy for high grade glioma (Protocol). *Cochrane Database of Systematic Reviews*, 2010 (2), 1-9.

Stewart, T., Pavlakis, N., Ward, M. (2010). Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. *Internal Medicine Journal*, 40(4), 303-307. [More Information]

Asmis, T., Powell, E., Karapetis, C., Jonker, D., Tu, D., Jeffery, M., Pavlakis, N., Gibbs, P., Zhu, L., Dueck, D., et al (2010). Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. *Annals of Oncology*, 22(1), 118-126. [More Information]

Tebbutt, N., Karapetis, C., Segelov, E., Pavlakis, N., Cunningham, D., Sobrero, A., Haller, D., Shapiro, J. (2010). Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. *Clinical Colorectal Cancer*, 9(1), 8-14. [More Information]

Kao, S., Pavlakis, N., Harvie, R., Vardy, J., Boyer, M., van Zandwijk, N., Clarke, S. (2010). High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. *Clinical Cancer Research*, 16(23), 5805-5813. [More Information]

Oh, B., Butow, P., Mullan, B., Clarke, S., Beale, P., Pavlakis, N., Kothe, E., Lam, L., Rosenthal, D. (2010). Impact of Medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. *Annals of Oncology*, 21(3), 608-614. [More Information]

Khasraw, M., Pavlakis, N., McCowatt, S., Underhill, C., Begbie, S., De Souza, P., Boyce, A., Parnis, F., Lim, V., Harvie, R., et al (2010). Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. *Annals of Oncology*, 21(6), 1302-1307. [More Information]

href="http://dx.doi.org/10.1093/annonc/mdp524">[More Information]

Khasraw, M., Townsend, A., Price, T., Hart, J., Bell, D., Pavlakis, N. (2010). Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours. *Internal Medicine Journal*, 40(6), 453-458. [More Information]

Oh, B., Butow, P., Mullan, B., Clarke, S., Tattersall, M., Boyer, M., Beale, P., Vardy, J., Pavlakis, N., Larke, L. (2010). Patient-Doctor Communication: Use of Complementary and Alternative Medicine by Adult Patients with Cancer. *Journal of the Society for Integrative Oncology*, 8(2), 56-64. [More Information]

Crino, L., Dansin, E., Garrido, P., Griesinger, F., Laskin, J., Pavlakis, N., Stroiakovski, D., Thatcher, N., Tsai, C., Wu, Y., et al (2010). Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. *The Lancet Oncology*, 11(8), 733-740. [More Information]

Evans, K., Richardson, M., Pavlakis, N., Morris, D., Liauw, W., Bester, L. (2010). Survival Outcomes of a Salvage Patient Population after Radioembolization of Hepatic Metastases with Yttrium-90 Microspheres. *Journal of Vascular and Interventional Radiology*, 21(10), 1521-1526. [More Information]

Oh, B., Butow, P., Mullan, B., Beale, P., Pavlakis, N., Rosenthal, D., Clarke, S. (2010). The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia. *Asia-Pacific Journal of Clinical Oncology*, 6(4), 342-349. [More Information]

2009

Stordal, B., Pavlakis, N., Davey, R. (2009). A systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy. In Andrea Bonetti, Roberto Leone, Franco M Muggia, Stephen B Howell (Eds.), *Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications*, (pp. 225-230). US: Humana Press. [More Information]

Khasraw, M., Atkinson, C., Van der Saag, D., Pavlakis, N., Guminski, A. (2009). Cardiac toxicity from sunitinib: Do we need to be more vigilant? *Asia-Pacific Journal of Clinical Oncology*, 5(4), 217-218. [More Information]

Au, H., Karapetis, C., O'Callaghan, C., Tu, D., Moore, M., Zalberg, J., Kennecke, H., Shapiro, J., Koski, S., Pavlakis, N., et al (2009). Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. *Journal of Clinical Oncology*, 27(11), 1822-1828. [More Information]

Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., et al (2009). Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. *Cancer Research*, 69(19), 7696-7703. [More Information]

Khasraw, M., Gill, A., Harrington, T., Pavlakis, N., Modlin, I. (2009). Management of Advanced Neuroendocrine Tumors With Hepatic Metastasis. *Journal of Clinical Gastroenterology*, 43(9), 838-47. [More Information]

Krieger, L., Pavlakis, N. (2009). Phase III trials of neo-adjuvant chemotherapy in Stage IIIA non-small cell lung cancer. Does size matter? *Asia-Pacific Journal of Clinical Oncology*, 5(2), 73-75.

Van Hazel, G., Pavlakis, N., Goldstein, D., Olver, I., Tapner, M., Price, D., Bower, G., Briggs, G., Rossleigh, M., Taylor, D., George, J. (2009). Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy. *Journal of Clinical Oncology*, 27(25), 4089-4095. [More Information]

2008

Nowak, A., Feigen, M., Pavlakis, N. (2008). Clinical trials in mesothelioma: Australasia? In A Baldi (Eds.), *Mesothelioma from Bench Side to Clinic*, (pp. 501-519). United States: Nova Science Publishers.

Herbertson, R., Karapetis, C., Price, T., Tebbutt, N., Pavlakis, N. (2008). Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancer. *Cochrane Database of Systematic Reviews*, 2, CD007047.

Krieger, L., Pavlakis, N. (2008). Evolution of biological therapies in non-small cell lung cancer. *Cancer Forum*, 32, 147-150.

Gananadha, S., Hazebroek, E., Leibman, S., Berry, H., Osgood, L., Shon, I., Pavlakis, N., Marx, G., Smith, G. (2008). The utility of FDG-PET in the preoperative staging of esophageal cancer. *Diseases of the Esophagus*, 21(5), 389-394. [More Information]

2007

Stordal, B., Pavlakis, N., Davey, R. (2007). A systematic review of platinum and taxane resistance from bench to clinic: An inverse relationship. *Cancer Treatment Reviews*, 33(8), 688-703. [More Information]

Stordal, B., Pavlakis, N., Davey, R. (2007). Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. *Cancer Treatment Reviews*, 33, 347-357. [More Information]

Desai, J., Gurney, H., Pavlakis, N., McArthur, G., Davis, I. (2007). Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management. *Asia-Pacific Journal of Clinical Oncology*, 3(4), 167-176. [More Information]

2006

Pavlakis, N., Patel, D., Stockler, M. (2006). Biphosphonates in early prostate cancer. *Cochrane Database of Systematic Reviews*, 4, CD006249.

Pavlakis, N. (2006). Drug treatment of renal cancer. *Australian*

Prescriber, 29, 159-161.

Pavlakakis, N., Vogelzang, N. (2006). Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma. *Expert Opinion on Biological Therapy*, 6(4), 391-399. [More Information]

2005

Pavlakakis, N., Schmidt, R., Stockler, M. (2005). Bisphosphonates for breast cancer. *Cochrane Database of Systematic Reviews*, (3), CD003474. [More Information]

Pavlakakis, N., Vogelzang, N. (2005). Second-line chemotherapy. In Harvey I Pass, Nicholas J Vogelzang, Michele Carbone (Eds.), *Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies*, (pp. 607-615). United States of America: Springer.

2003

Pavlakakis, N., Stockler, M. (2003). Bisphosphonates for breast cancer. *Cochrane Database of Systematic Reviews*, 11.

2002

Pavlakakis, N., Stockler, M. (2002). Bisphosphonates in breast cancer. *Cochrane Database of Systematic Reviews*, , 1-28.

2001

Pavlakakis, N., Laurent, R. (2001). Role of the observed long case in postgraduate medical training. *Internal Medicine Journal*, 31, 523-528.